GUILDFORD, England, April 20,
2015 /PRNewswire/ -- ANGLE plc (AIM:AGL OTCQX:ANPCY),
the specialist medtech company, is pleased to announce that the
Sidney Kimmel Cancer Center at Thomas
Jefferson University, Philadelphia, one of its key opinion leaders,
has published results of its work evaluating the potential for
ANGLE's Parsortix system to be used in single cell analysis for
breast cancer.
The results are being published as a poster at the American
Association for Cancer Research Annual Meeting 2015 being held in
Philadelphia ("AACR"). AACR
is one of the world's largest and most influential cancer
conferences. The poster can be downloaded from the ANGLE
website here
http://www.angleplc.com/the-parsortix-system/download-files/.
A key challenge in investigating the metastatic process and
improving the therapeutic benefit of cancer treatment is the
heterogeneity (genetic variability) of the cancer cells.
There are major potential benefits if circulating tumour cells
(CTCs) can be harvested from patient blood and then processed
individually one-by-one as intact cells for analysis.
Technically this requires a high performance CTC capture and
harvesting system that provides harvested CTCs in a form capable of
then being processed by a single cell analysis system.
The Sidney Kimmel Cancer Center at Thomas
Jefferson University have successfully tested the Parsortix
system in combination with the single cell analysis DEPArray system
to isolate single cancer cells from blood samples spiked with
cultured breast cancer cells. The team proved the ability to
manipulate the individual cancer cells from the Parsortix system
and to correctly identify two breast cancer related genes (Estrogen
receptor alpha (ESR1) and p53) on the cells using standard PCR
analysis techniques.
The research collaboration was led by Dr. Massimo Cristofanilli, an internationally
renowned breast cancer researcher and clinician, and Director of
the Jefferson Breast Care Center at the Sidney Kimmel Cancer Center
and Thomas Jefferson University and
Hospitals. Dr Cristofanilli has been an acknowledged leader
in the CTC field since 2004, when his study on CTCs was published
in The New England Journal of Medicine.
The work will now focus on molecular analysis in specified
disease status and treatment settings to better identify clinical
applications for more effective treatment of women with metastatic
breast cancer.
Dr Massimo Cristofanilli,
Director of the Jefferson Breast Care Center at the Sidney Kimmel
Cancer Center and Thomas Jefferson
University and Hospitals, commented:
"We
demonstrated that using the Parsortix system in conjunction with
DEPArray we are able to isolate single, uncontaminated tumor cells
to achieve single cell molecular analysis. The use of single cells
is emerging as a powerful approach to molecular analysis in
oncology. The Parsortix system has the ability to advance molecular
testing, study cancer heterogeneity and apply concepts of precision
medicine to breast cancer patients' care."
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The ability
to capture and harvest individual CTCs for routine analysis is an
important step that has proved extremely difficult until now.
Our aim is that the Parsortix system will provide a simple and
effective way to harvest CTCs for mutation, gene expression and
other types of molecular analysis so that there is a way to
determine which drugs may benefit individual patients."
www.angleplc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/results-from-the-sidney-kimmel-cancer-center-at-thomas-jefferson-university-300068341.html
SOURCE ANGLE plc
